GlassScriptPhysician profile
Michelle Moscow
NPI 1598285447
$12,454.22
in general payments reported to CMS, 2019-2025
21 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $758 · 2021: $2,286 · 2022: $2,228 · 2023: $1,184 · 2024: $2,548 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,029 · Entertainment: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,028.61 |
| Entertainment | $222.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,812.71 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $2,119.84 | 2022-2025 | Infuse, Alden Scleral Zenlens, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,267.38 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $1,076.65 | 2020-2025 | Cequa |
| Sight Sciences, INC. | $978.47 | 2019-2024 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $687.59 | 2019-2023 | |
| Glaukos Corporation | $463.92 | 2023-2024 | Ce-Marked Kxla System |
| Visioneering Technologies, INC. | $249.73 | 2019-2024 | |
| Optos, INC. | $247.04 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $198.70 | 2022 | |
| Dompe US, INC. | $197.72 | 2022-2024 | Oxervate |
| Harrow Eye, LLC | $186.81 | 2025 | Vevye |
| Shire North American Group INC | $158.74 | 2019 | |
| Alcon Vision LLC | $157.03 | 2022-2025 | Dailies Total1 |
| Tarsus Pharmaceuticals, INC. | $152.81 | 2024 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $105.12 | 2021 | |
| Lkc Technologies, INC. | $99.61 | 2025 | |
| Kala Pharmaceuticals, INC. | $96.53 | 2021-2022 | |
| Abb Con-Cise Optical Group LLC | $83.81 | 2022 | |
| Biotissue Holdings INC. | $79.70 | 2019 | |
| Allergan, INC. | $34.31 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Moscow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.